SCHEMBL2111624

SCHEMBL2111624

O=S(=O)(Cl)NCCCCl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2112171 0.82
SCHEMBL2582338 0.76
SCHEMBL3365101 0.76
SCHEMBL11827999 0.76
SCHEMBL11400916 0.76
SCHEMBL22955433 0.75 EPHX1 (0.39)
SCHEMBL1158769 0.74 PPARA (0.58)
Bromide SCHEMBL11828014 0.74 GRIA1 (0.34)
Hydrochloric Acid SCHEMBL27980386 0.74 GRIA1 (0.34)
Hydrochloric Acid SCHEMBL20522443 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4604955-A1 USE OF PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3 COMPOUNDS Pfizer Inc. (US) 2025-08-27 EP disclosed
EP-4605076-A1 PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3 (PNPLA3) MODIFIERS Pfizer Inc. (US) 2025-08-27 EP disclosed
CN-120129681-A Modulators of protein 3 (PNPLA 3) containing Patatin-like phospholipase domains 辉瑞大药厂 2025-06-10 CN disclosed
WO-2025103502-A1 COMPOUNDS AND METHODS OF TREATING CANCERS CULLGEN INC. (US) 2025-05-22 WO disclosed
WO-2024084360-A1 PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3 (PNPLA3) MODIFIERS PFIZER INC. (US) 2024-04-25 WO disclosed
WO-2024084363-A1 USE OF PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING PROTEIN 3 COMPOUNDS PFIZER INC. (US) 2024-04-25 WO disclosed
CN-105916503-B Heteroaryl compounds and uses thereof 米伦纽姆医药公司 2020-04-14 CN disclosed
US-10538533-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2020-01-21 US disclosed
US-10538533-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2020-01-21 US disclosed
US-20180118762-A1 HETEROARYLS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-03 US disclosed
US-7713961-B2 Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-11 US disclosed
US-7713961-B2 Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-11 US disclosed
US-20090325940-A1 Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-12-31 US disclosed
US-20090325940-A1 Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-12-31 US disclosed
US-20090042867-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE FUCHS KLAUS 2009-02-12 US disclosed
US-20090042867-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE FUCHS KLAUS 2009-02-12 US disclosed
WO-2007017509-A1 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-02-15 WO disclosed
WO-2007017507-A1 BETA-SECRETASE INHIBITORS FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-02-15 WO disclosed
WO-2007017511-A2 COMPOUNDS FOR TREATING ALZHEIMER'S DISEASE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-02-15 WO disclosed
WO-2007017510-A2 ISOPHTHALIC ACID DIAMIDES FOR TREATING ALZHEIMER'S DISEASE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-02-15 WO disclosed